After adjusting for confounding factors, females had a 64% increased risk of developing MH compared with males (adjusted hazard ratio, 1.64; 95% CI, 1.11-2.43; P = .01), with the effect of sex varying across ages. Compared with white participants, Asian-American enrollees had a 177% increased risk of developing MH (adjusted hazard ratio, 2.77; 95% CI, 1.27-6.02; P = .01).
M acular hole (MH) is a reversible cause of decreased vision among older Americans. As such, MH can greatly reduce health-related quality of life. 1 A better understanding of risk factors for MH may help clarify the pathophysiologic factors of this condition and identify potential new avenues for preventing and treating MHs. After adjusting for age and sex, it is estimated that 7.8 per 100 000 persons per year are newly diagnosed with MH. 2 Prior reports have found that 80% of cases are unilateral, while twothirds of patients are women. 3 Although female sex is a wellestablished risk factor, 4 additional risk factors for developing
MHs are not known. 5 Population-based studies have been limited in size, with the largest study, to our knowledge, reporting on only 100 persons who developed MH. 2 Moreover, prior studies have been limited regionally to areas of relative racial homogeneity. 2, [6] [7] [8] The only study, to our knowledge, to estimate the incidence of MH was performed from 1992 to 2002 and identified patients with MH based on results of clinical examination without the use of optical coherence tomography. 2 This study uses health care claims data from a cohort of more than 2 million enrollees in a large managed care network throughout the United States who were followed up longitudinally from 2001 to 2012 to study the incidence of and relevant risk factors for MH. These analyses will help confirm previous reports and expand upon earlier work by using a large sample size to assess sociodemographic factors and ocular and nonocular conditions as potential risk factors.
Methods

Data Source
The Clinformatics DataMart database (OptumInsight) contains detailed health care claims data for all beneficiaries in a large, nationwide, US managed care network. This data set contains all individuals with 1 or more International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes for eye-related diagnoses (360-379.9); 1 or more Current Procedural Terminology (CPT) codes for eye-related visits or diagnostic or therapeutic procedures (65091-68899 or 92002-92499); or any other claim submitted by an ophthalmologist or optometrist from January 1, 2001 , to December 31, 2012. The database includes claims for all ocular and nonocular conditions along with sociodemographic information on each enrollee, including age, sex, race/ethnicity, educational level, and estimated household net worth. This database has been validated for studying patients with ocular diseases.
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Participants and Sample Selection Individuals were included in the analysis if they met the following criteria: 40 years or older, continuous enrollment in the medical plan for at least 3 years, and 2 or more visits to an ophthalmologist or optometrist. We excluded persons younger than 40 years because prior large population-based studies have reported that MH is rare in persons of younger ages. 2, 12, 13 Individuals were also excluded if they received a diagnosis of MH during the first 3 years they were enrolled in the plan so as to exclude those who may have had the condition before plan entry (nonincident cases). Persons with records of diabetes or uveitis while enrolled in the plan were also excluded to minimize the potential for capturing macular cyst pathologic findings that may have been misdiagnosed or miscoded as MH. The University of Michigan Institutional Review Board approved this study based on the use of aggregate deidentified data.
Identifying Persons Newly Diagnosed With MH
To be counted as an incident MH case, the enrollee must have had at least 1 visit to see an eye care professional during his or her first 3 years in the plan with no documented diagnosis of MH and no record of vitrectomy surgery (a common treatment for MH) during the first 3 years in the plan. The enrollee must have then had a subsequent visit to an eye care professional after the index date (3 years after their entry into the plan) with an ICD-9-CM code for MH (362.54). To be even more certain that the enrollee indeed had MH and it was not a miscoded diagnosis, we required a record of vitrectomy surgery for MHs (CPT code 67042) within 90 days of the initial diagnosis of MH to be counted as a case. This specific code for MH surgery was introduced in 2008. As such, only individuals with an index date after January 1, 2009, were included. For these analyses, persons coded with a diagnosis of MH but with no record of vitrectomy were not counted as cases.
Statistical Analysis
Statistical analyses were performed from December 1, 2014, to August 15, 2016, using SAS, version 9.4 (SAS Institute Inc). Participant characteristics were summarized for the entire sample using means and SDs for continuous variables and frequencies and percentages for categorical variables.
The cumulative incidence of MH was defined as the number of cases divided by the number of person-years from the index date to the date of the last visit to an eye care professional. Risk of developing MH was also evaluated by KaplanMeier life-table analysis. Wilcoxon log-rank tests were used to compare the probability of MH formation by age, sex, and race/ ethnicity.
Multivariable Cox proportional hazards regression with delayed entry was used to estimate the risk of being diagnosed with MH requiring vitrectomy surgery. P < .05 was considered significant. All beneficiaries were followed up in the model from the index date (3 years after plan entry) until they were first diagnosed with MH and underwent vitrectomy or were censored. Censoring occurred at the date of the last eye examination, which marked the last opportunity to receive a diagnosis of MH from an eye care professional.
Multivariable models were adjusted for age; sex; race/ethnicity; educational level; income; region of residence at the time of enrollment in the medical plan; residence in an urban or rural setting; cataract, eye trauma, pseudophakia, or aphakia; and hypertension, hyperlipidemia, cerebrovascular accident, myocardial infarction, congestive heart failure, and depression.
A broader sensitivity analysis to capture cases before 2008 was also performed. The following CPT codes were queried, which were used for coding MH surgery before the introduction in 2008 of more specific coding for vitreoretinal surgery: 1471, 1472, 1473, 1474, 1475, 1479, 67036, 67038, 67039, 67040, 67041, 67042, 67043, 67108, 67112, and 67113. These codes needed to be dated within 90 days of the initial diagnosis of MH to be counted as a case.
Results
A total of 659 357 beneficiaries met the inclusion criteria; 144 (0.02%) developed MH that required vitrectomy during the study period. The mean (SD) age of individuals who developed MH was 62.6 (6.3) years and was 56.2 (9.2) years for those who did not develop MH (P < .001) ( Table 1 ). The mean (SD) duration of follow-up for individuals who developed MH was 2.3 (0.9) years and for those who did not was 1.4 (1.1) years (P < .001). Among the 144 individuals who developed MH, 105 (72.9%) were female. The racial distribution of those diagnosed with MHs included 109 white individuals (79.0%), 16 black individuals (11.6%), 4 Latino individuals (2.9%), 7 Asian individuals (5.1%), and 2 persons of other races/ethnicities (1.4%); 6 individuals were missing data on race/ethnicity.
Cumulative Incidence of MH
The cumulative incidence of MH formation was 41.1 cases per 100 000 person-years. In males, the cumulative incidence was 34.1 cases per 100 000 person-years, while in women, the cumulative incidence was 55.9 cases per 100 000 person-years.
The cumulative incidence of MH formation increased with age. Per 100 000 person-years, there were 6.0 cases in individuals aged 40 to 49 years, 30.3 cases in those aged 50 to 59 years, 98.2 cases in those aged 60 to 69 years, and 77.1 cases in individuals 70 years or older.
The cumulative incidence of MH formation varied across races/ethnicities: per 100 000 person-years, there were 45.7 cases in white individuals, 60.1 cases in black individuals, 29.5 cases in Latino individuals, and 94.5 cases in Asian individuals.
Risk Factors Associated With Development of MH Sociodemographic Factors
After adjusting for potential confounders, females had a 64% increased risk of being diagnosed with MH compared with males (adjusted hazard ratio [aHR], 1.64; 95% CI, 1.11-2.43; P = .01) ( Table 2) . Asian-American enrollees had a 177% increased risk of developing MH compared with white individuals (aHR, 2.77; 95% CI, 1.27-6.02; P = .01). Black enrollees (aHR, 1.54; 95% CI, 0.86-2.76; P = .15), Latino enrollees (aHR, 0.94; 95% CI, 0.35-2.58; P = .91), and persons of other races/ethnicities (aHR, 2.33; 95% CI, 0.57-9.45; P = .24) did not have an increased risk of developing MH vs white enrollees.
We found a nonlinear effect of age on the risk of developing MH. Age had an increased effect on the hazard of MH initially, followed by a decreased effect after age 75.2 years. ); and at age 76.2 years, the HR was 0.83 (95% CI, 0.43-1.63).
Ocular Comorbidities
After adjusting for confounders, persons diagnosed with cataract had an 86% increased risk of developing MH compared with individuals without cataracts (aHR, 1.86; 95% CI, 1.22-2.82; P = .004) ( Table 2) . A diagnosis of pseudophakia or aphakia was associated with more than a 2-fold increased risk of developing MH (aHR, 3.66; 95% CI, 2.46-5.44; P < .001).
Systemic Comorbidities
After adjusting for potential confounders, individuals with hypertension, myocardial infarction, cerebrovascular accident, hyperlipidemia, or congestive heart failure did not have a significantly different hazard of MH formation compared with those individuals without each of these conditions, respectively (Table 2) .
Sensitivity Analysis
The results using available vitrectomy coding that dated back to 2001 were similar to those of the primary, more restricted analysis using coding more specific for MH surgery that was instituted in 2008 (eTable 1 and eTable 2 in the Supplement). The cumulative incidence of MH formation was 40.8 cases per 100 000 person-years. Females had a 68% increased hazard of being diagnosed with MH compared with males of the same age.
Interaction of Age and Sex and MH
Age was determined to have a second-order effect on the risk of developing MH; an interaction between age and sex was also found ( Table 4) . Age is seen to have an increased effect on the risk of MH for both males and females initially, followed by a decreased effect after age 77.7 years for females and age 84.1 years for males ( Figure) . Table 4 Log-rank testing revealed differences in MH development by age (log-rank χ 2 statistic = 490.3, df =2 ;P < .001) and sex (log-rank χ 2 statistic = 17.3, df =1 ;P < .001) but not race/ethnicity (log-rank χ 2 statistic = 6.5, df =4 ; P = .17). 
Discussion
Using a large, nationwide, US managed care database, our study confirms the known association between age and female sex with the risk for developing idiopathic MHs. This database captures a cohort of 144 persons who were followed up longitudinally for newly diagnosed MH that required surgical repair with vitrectomy. We learned that not only does the probability of developing MH significantly increase with age but also that older age affects the risk of development of MH considerably more for women (64% more likely in a woman than in a man of the same age).
Limitations
We acknowledge that our study has several limitations. Given that the diagnosis of MH is made exclusively based on claims data, it is possible that some patients were misdiagnosed or miscoded. To mitigate misclassification coding for vitrectomy of MH as opposed to vitrectomy performed for epiretinal membrane and/or macular cyst, we performed a primary analysis capturing individuals with new MH requiring coding specific for pars plana vitrectomy for MH (CPT code 67042), which was instituted in 2008. Our secondary analysis used the more broadly applied coding that was used before 2008. Even though our primary analysis limited our sample size considerably, both analyses yield similar cumulative incidence and risk factors for MH requiring vitrectomy, while the former draws from a smaller sample but is more specific, and the latter draws from a larger sample but is susceptible to miscoding. The true estimated risk is likely to lie between the more restrictive estimate generated through the primary analysis and the findings from the less restrictive secondary analysis. To mitigate misclassification of the diagnosis of MH in patients who actually had cystoid macular edema and not MH, we excluded individuals with diabetes or uveitis. As such, the findings of our analyses cannot be generalized to these groups of patients and are not generalizable to MHs in the entire population but are specifically aimed toward capturing idiopathic disease.
Moreover, given our requirement of concurrent coding for vitrectomy along with exclusion of patients with diabetes and uveitis, we suspect that very few cases were misclassified in both analyses. Our study captures visually significant, laterstage MHs but not earlier-stage MHs or individuals with laterstage MHs that did not proceed to undergo vitrectomy, which likely results in an underestimate of the incidence of MH in our population.
Although there are many advantages to using claims data, our source lacks important clinical information, such as bestcorrected visual acuity, and findings from ancillary tests, such as optical coherence tomography, that can affect the ability to diagnose and manage MH.
Finally, our study included individuals who all had commercial health insurance. Caution should be taken when applying the findings to those with other types of coverage or no coverage. Also, given our inclusion criteria requiring at least 2 visits to an eye care professional, it is possible that individuals seeking routine eye care may be systematically different from those who do not and may bias our results toward capturing more cases than would be represented in the general population. Past research has demonstrated that age is an important risk factor for the development of MH. Liquefaction of the vitreous and the development of posterior vitreous detachments (PVDs) increase with older age. Given that PVDs are known to increase the predisposition for development of MH, 3, 14 this finding likely explains some of the heightened risk of MH among older individuals. Furthermore, with aging, many patients undergo cataract surgery, which has also been shown to increase the risk of PVDs, which can, in turn, lead to development of MH. 15 Our finding that females have a higher risk of developing MHs relative to males is consistent with other studies in the literature. 2, 4, 8, 13 The precise etiologic factors for the increased risk of MH in women are unknown, although several theories have been proposed. Postmenopausal women are more prone to PVD compared with male counterparts of similar age. This finding is thought to be associated with the effects of decreased estrogen in the vitreous gel. 16 Similarly, there are reports that estrogen replacement therapy is associated with a reduction in the risk of idiopathic MHs. 5 We hypothesize that estrogen changes during perimenopausal years play a role in the cross-linking and loss of vitreous collagen and glycosaminoglycans that occurs with vitreous liquefaction, subsequent vitreomacular traction, and the onset of MH pathologic findings. To our knowledge, no prior studies report an association between race/ethnicity and the risk of MHs. Our study revealed that Asian individuals have a higher risk of development of MH compared with white individuals. We suspect this finding may be owing, in part, to greater proportions of Asian individuals with myopia, an established risk factor for MH. 17, 18 Unfortunately, our data source lacks information on the level of refractive error for enrollees to incorporate this variable into regression models. Additional research is required to substantiate the association between Asian ethnicity and development of MH.
Another interesting finding from our analyses is the increased risk of MH associated with cataracts or pseudophakia or aphakia. Since cataract surgery can hasten the development of PVD and PVD predisposes patients to MH, this finding may help explain the higher risk of MH in patients with pseudophakia or aphakia. Also, it is possible that removal of the cataract revealed an underlying MH that was not noted preoperatively but became a new diagnosis when the patient became pseudophakic. Similarly, it is possible that visual impairment from MH may have been concordantly documented as visual impairment from cataract in the setting of combined surgery for both pathologic conditions. Additional research is needed to determine whether cataracts alter the anatomy of the eye in a manner that increases the risk of MH or whether there are other explanations for the increased risk.
Most prior studies examining the epidemiologic factors of MH have assessed the prevalence, but not the incidence, of MH as we have done here. 8 To our knowledge, there is only 1 study assessing the incidence of MH among persons residing in Olmsted County, Minnesota, between 1992 and 2002. 2 Comparison of the findings from our study with this past analysis is challenging for many reasons. First, the sociodemographic characteristics of the patients differ between the 2 cohorts. Second, our study was conducted a decade later than the Olmsted County study. Advances in ancillary diagnostic tests, such as optical coherence tomography that help facilitate the diagnosis of MH, likely made it much easier to diagnose MH in our analysis. On the other hand, our study captures only patients with MHs that required surgical repair, while the prior study captured patients with all stages of MH. Thus, we are likely underestimating the true incidence of this condition. Finally, there may be differences in the level of experience and expertise at diagnosing MH among the eye care professionals evaluating patients in the 2 studies. Our sample size allows us to control for several important potential confounding factors. Given that the patients identified with MHs all underwent vitrectomy surgery, it is likely that nearly all were under the care of retinal specialists who are qualified to diagnose MHs. Finally, unlike single-center studies, our analysis captures patients receiving care in various set- Kaplan-Meier plot of survival probabilities by follow-up time, stratified by age at index date. The survival probability curves for the older groups drop off after 1000 days of follow-up, resulting in a significant difference in survival probability between the age groups (P<.001).
eFigure 2. Relationship of Sex and Development of Macular Holes
Kaplan-Meier plot of survival probabilities by follow-up time, stratified by sex. Females have a significantly lower probability of survival compared to males (P<.001).
eFigure 3. Relationship of Race and Development of Macular Holes
Kaplan-Meier plot of survival probabilities by follow-up time, stratified by race. Though Latinos appear to have the highest probability of survival, followed by whites and then blacks, there is no statistically significant difference between the races. Asian patients were omitted from the figure due to limited length of followup. 
